Skip to content Skip to navigation


Rod Page, "Current Resources and Experiences with Naturally Occurring Cancer in Companion Animals: Biology, Experimental Therapeutics and Public Awareness"

Spontaneously developing cancers in companion animals have been considered a relevant system to interrogate the etiology, evolution and treatment of human cancers for over 50 years. Innovations across all modalities of therapeutic interventions have been investigated, including surgery, radiation, gene therapy and targeted small molecules. Current efforts to expand the role of comparative oncology research will be summarized in this presentation, including foundational science needs, the business case for industry adoption of comparative oncology resources and campaigns to build awareness and education.   

See talk slides

Antonella Borgatti, "The Animal Cancer Care and Research Program - Vision and Opportunities"

Cancer remains the leading cause of disease-related death in dogs and the leading cause of death in humans under the age of 85. The Animal Cancer Care and Research (ACCR) Program at the University of Minnesota is the only program in the United States housed and administered jointly between a College of Veterinary Medicine and a National Cancer Institute-designated Comprehensive Cancer Center, The Masonic Cancer Center. Through collaborations and innovative research ACCR researchers are determined to achieve their goal of creating a world where we no longer fear cancer. ACCR primarily focuses on advancing knowledge and translating it to reduce the impact of cancer in both animal and human patients. This presentation will highlight the resources offered by our research program, and briefly summarize previous collaborations with Stanford University and recently completed and ongoing clinical trials. 

See talk slides

Michael Kent, "Comparative Oncology – The UC Davis Approach"

The comparative oncology approach requires an understanding of the model and its limitations. A knowledge of canine cancer and how it compares to human cancer, defining specific questions that can be best answered by the model, understanding what reagents are available and which ones aren’t and most of all understanding that client owned animals are not laboratory animals.  This talk will review some recently completed trials and highlight some of the comparative oncology trials being carried out at UC Davis, including those in immune-oncology. 

See talk slides

Amy LeBlanc, "The NCI Comparative Oncology Program: Past, Present and Future"

Amy will provide an overview of the NCI’s Comparative Oncology Program infrastructure and goals, along with key examples of comparative oncology clinical trials that have been conducted and/or are currently open for enrollment. These examples demonstrate how the comparative approach to cancer drug development can ask and answer specific questions not sufficiently addressed with rodent models or human trials. She will also introduce several new initiatives being spearheaded by the COP, including a comparative brain tumor consortium and imaging dogs with naturally-occurring cancers on the NIH campus.

See talk slides

***Talk discussion transcripts coming soon